DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives

Drugs · Published 2026-07-29 · DOI 10.1007/s40265-026-02355-5

Free full text

Authors (16)

Giovanna Pecoraro, Alberto De Giorgi, Giulia Montelatici, Giuseppe Salfi, Hui-Ming Lin, Fabio Turco, Tarek Taha, Himisha Beltran, Johann de Bono, Rahul Raj Aggarwal, Gunhild von Amsberg, Markus Joerger, Martina Imbimbo, Ilaria Colombo, Silke Gillessen, Martino Pedrani

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Pecoraro, G., Giorgi, A., Montelatici, G., et al. (2026). DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives. Drugs. https://doi.org/10.1007/s40265-026-02355-5

Related articles

• DLL3 Expression in Neuroendocrine Carcinomas and Neuroendocrine Tumours: Insights From a Multicentric Cohort of 1294 Pulmonary and Extrapulmonary Neuroendocrine Neoplasms · Endocrine Pathology · 2025 · Cites or is cited by this article
• Emerging Variants of Castration-Resistant Prostate Cancer · Current Oncology Reports · 2017 · Cites or is cited by this article
• Expression of DLL3 and SEZ6 in the Spectrum of Neuroendocrine Neoplasia · Endocrine Pathology · 2025 · Cites or is cited by this article
• Sibeprenlimab: First Approval · Drugs · 2026 · Same journal
• The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir · Drugs · 2026 · Same journal
• Ecnoglutide: First Approvals · Drugs · 2026 · Same journal
• Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering · Drugs · 2026 · Same journal
• Etripamil: First Approval · Drugs · 2026 · Same journal
• Long-Acting Lipoglycopeptide Treatment of Invasive Gram-Positive Infections · Drugs · 2026 · Same journal
• Emerging Cardiorenal Protective Therapies in Lupus Nephritis · Drugs · 2026 · Same journal